Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer

Tango Therapeutics announced updated Phase 1/2 clinical trial results showing an 82% objective response rate and 88% progression-free survival at nine months for its experimental PRMT5 inhibitor vopimetostat combined with Revolution Medicines' Rasonque in advanced pancreatic cancer. Despite exceeding analyst benchmarks, Tango shares fell nearly 18% on October 23, 2026, relative to an earlier 92% response rate in June. Tango plans to seek FDA accelerated approval guidance for second-line treatment, launch a Phase 3 trial in early 2027 for front-line MTAP-deleted cases, and reduce its workforce by 14% to prioritize clinical execution.

Phase 1/2 trial efficacy results

• ▪Tango Therapeutics previously reported June 2026 data from 12 patients in its vopimetostat-Rasonque trial showing a 92% response rate and a six-month progression-free survival rate of 90%
• ▪An updated Phase 1/2 trial of Tango Therapeutics' vopimetostat combined with Revolution Medicines' Rasonque (daraxonrasib) showed an 82% objective response rate in 22 evaluable patients with advanced pancreatic cancer
• ▪In the Phase 1/2 trial of vopimetostat and Rasonque, progression-free survival was 88% at nine months for patients with second- or third-line pancreatic cancer

Trial dosing and tolerability

• ▪In the Phase 1/2 trial of vopimetostat and Rasonque, dose level 1 consisting of 200 mg vopimetostat and 600 mg daraxonrasib daily was well-tolerated in 25 patients without dose-limiting toxicities
• ▪Dose level 2 consisting of 250 mg vopimetostat and 600 mg daraxonrasib was not well-tolerated, causing dose-limiting toxicities in three of four patients

Analyst reactions to trial data

• ▪Jefferies analysts stated in a Thursday note that the updated data from Tango's vopimetostat-Rasonque trial met expectations by surpassing their 70% benchmark for objective response rate
• ▪William Blair analysts noted on Thursday that data from Tango's Phase 1/2 trial support a highly synergistic effect between vopimetostat and daraxonrasib, though first-line pancreatic cancer trends remain difficult to conclude

Future clinical and regulatory strategy

• ▪CEO Malte Peters said Tango Therapeutics plans to launch a Phase 3 trial in the first half of 2027 evaluating vopimetostat and daraxonrasib against standard chemo in first-line pancreatic cancer with MTAP deletions
• ▪Approximately 40% of patients diagnosed with pancreatic cancer carry an MTAP deletion, according to Tango Therapeutics CEO Malte Peters
• ▪Tango Therapeutics CEO Malte Peters stated the company will seek FDA guidance on an accelerated approval pathway for vopimetostat plus daraxonrasib in second-line pancreatic cancer

Tango Therapeutics stock performance

• ▪Tango Therapeutics shares had previously surged 43% to $28.94 at market open on June 8, 2026, after initial 12-patient vopimetostat-Rasonque trial data were announced
• ▪Tango Therapeutics stock fell nearly 18% from the previous day's close to $22.91 on October 23, 2026, following the release of updated results from its Phase 1/2 vopimetostat-Rasonque trial

FDA decisions on Rasonque

• ▪The U.S. Food and Drug Administration approved Revolution Medicines' Rasonque (daraxonrasib) for second-line pancreatic adenocarcinoma on August 26, 2026, 6.5 months ahead of the FDA's deadline
• ▪The U.S. Food and Drug Administration granted Breakthrough Therapy Designation to Revolution Medicines' daraxonrasib for first-line pancreatic cancer in September 2026

Tango Therapeutics workforce reduction

• ▪Tango Therapeutics had 137 full-time staffers including 97 research and development employees as of December 31, 2025
• ▪Tango Therapeutics disclosed in an SEC filing on October 23, 2026, that it will reduce its total workforce by 14%, eliminating approximately 19 positions mostly in research